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Transgenic mousea b s t r a c t
Background and objective: Senescence marker protein 30 (SMP30) is assumed to behave as an anti-aging
factor. Recently, we have demonstrated that deﬁciency of SMP30 exacerbates angiotensin II-induced car-
diac hypertrophy, dysfunction and remodeling, suggesting that SMP30 may have a protective role in the
heart. Thus, this study aimed to test the hypothesis that up-regulation of SMP30 inhibits cardiac adverse
remodeling in response to angiotensin II.
Methods: We generated transgenic mice with cardiac-speciﬁc overexpression of SMP30 gene using a-
myosin heavy chain promoter. Transgenic mice and wild-type littermate mice were subjected to contin-
uous angiotensin II infusion (800 ng/kg/min).
Results: After 14 days, heart weight and left ventricular weight were lower in transgenic mice than in
wild-type mice, although blood pressure was similarly elevated during angiotensin II infusion. Cardiac
hypertrophy and diastolic dysfunction in response to angiotensin II were prevented in transgenic mice
compared with wild-type mice. The degree of cardiac ﬁbrosis by angiotensin II was lower in transgenic
mice than in wild-type mice. Angiotensin II-induced generation of superoxide and subsequent cellular
senescence were attenuated in transgenic mouse hearts compared with wild-type mice.
Conclusions: Cardiac-speciﬁc overexpression of SMP30 inhibited angiotensin II-induced cardiac adverse
remodeling. SMP30 has a cardio-protective role with anti-oxidative and anti-aging effects and could be
a novel therapeutic target to prevent cardiac hypertrophy and remodeling due to hypertension.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Senescence marker protein 30 (SMP30), a 34-kDa protein orig-
inally discovered in rat liver, is a marker of aging because itsexpression is decreased with age in an androgen-independent
manner [1]. SMP30 gene is located in the p11.3–q11.2 segment
of the X chromosome and highly conserved among vertebrates,
indicating a crucial physiological function of SMP30 in mammals
[2]. Moreover, SMP30 is widely distributed in almost all organs
including the heart. Previous studies conducted using SMP30
knockout (KO) mice have reported that SMP30 has protective ef-
fects against age-associated oxidative stress in brain and lungs
[3,4].
However, the functional role of SMP30 in the heart has not been
fully elucidated. We have recently demonstrated using SMP30-KO
mice that absence of SMP30 exacerbates angiotensin II-induced
generation of reactive oxygen species, cardiac remodeling and dys-
function, suggesting that SMP30 has a protective role with anti-
oxidative effects in the heart [5]. Here, we investigated whether
up-regulation of cardiac SMP30 gene inhibits generation of reac-
tive oxygen species, cardiac hypertrophy and remodeling in re-
sponse to angiotensin II. We generated transgenic mice with
cardiac-speciﬁc overexpression of SMP30 gene and tested the
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remodeling and dysfunction using a gain-of-functional approach
in vivo.
2. Material and methods
2.1. Animals
The investigations conformed to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH publication, 8th Edition, 2011). Our research protocol
was approved by the institutional review board, and all animal
experiments were conducted in accordance with the guidelines
of Fukushima Medical University Animal Research Committee.
Transgenic mice with cardiac-speciﬁc overexpression of SMP30
gene (SMP30-TG) were created using standard techniques with
murine a-myosin heavy chain gene promoter (a kind gift from
Dr. J. Robbins, Children’s Hospital Research Foundation, Cincinnati,
OH) as we previously reported [6,7]. The transgene composed of
the a-myosin heavy chain gene promoter, murine SMP30 cDNA,
and a poly A tail of the human growth hormone. We microinjected
the DNA construct into the pronuclei of single cell fertilized mouse
embryos to generate transgenic mice. To detect the exogenous
SMP30 gene, genomic DNA was extracted from the tail tissues of
3–4-weeks-old pups, and polymerase chain reaction (PCR) was
performed with one primer speciﬁc for the a-myosin heavy chain
gene promoter and another primer speciﬁc for the SMP30 as re-
ported previously [6,7].
2.2. Experimental protocol
Age-matched (12–16 weeks) male SMP30-TG mice and wild-
type (WT) littermate mice were randomly divided into angiotensin
II or control saline group. After anesthetizing the mice by intraperi-
toneal injection of pentobarbital (50 mg/kg body weight), an osmo-
tic minipump (ALZET micro-osmotic pump MODEL 1002, DURECT
Co., Cupertino, CA) was subcutaneously implanted, and angioten-
sin II (800 ng/kg per minute) or normal saline was continuously in-
fused for 14 days [5,8].
2.3. Measurement of vitamin C
Total vitamin C levels in the heart were measured by the dini-
trophenylhydrazine method according to the manufacturer’s pro-
tocol (SHIMA Laboratories Co. Ltd., Tokyo, Japan) [9].
2.4. Measurements of blood pressure and heart rate
After subcutaneous infusion of angiotensin II or saline, the sys-
tolic, mean and diastolic blood pressures and heart rate were mea-
sured by the tail-cuff method using a programmable
sphygmomanometer (BP-98A-L, Softron, Tokyo, Japan) under free
from anesthesia [5,8].
2.5. Echocardiography
After 2 weeks of angiotensin II infusion, echocardiography was
performed using Vevo 2100 High-Resolution In Vivo Imaging Sys-
tem (Visual Sonics Inc., Toronto, Canada) with a high-resolution
40-MHz imaging transducer as previous reports described [5,7].
Mice were lightly anesthetized by titrating isoﬂurane (0.5–1.5%)
to achieve a heart rate of around 400 beats/min. Parasternal
long-axis, short-axis, and apical four-chamber two-dimensional
images were acquired. With the use of the M-mode image from
the parasternal short-axis view at the papillary muscle level, intra-ventricular septal thickness (IVS), posterior wall thickness (PW),
left ventricular end-diastolic dimension (LVEDD), and left ventric-
ular end-systolic dimension (LVESD) were measured [5–7]. The
percentage of left ventricular fractional shortening (FS) was calcu-
lated as 100  ((LVEDD–LVESD)/LVEDD). Left ventricular mass was
calculated as 1.053  ((LVEDD + LVESD + IVS)3LVEDD3). Pulse
Doppler images were taken with the apical four-chamber view to
record the mitral Doppler inﬂow spectrum [5,10,11]. Peak early
diastolic left ventricular ﬁlling velocity (E) and peak atrial ﬁlling
velocity (A) were measured. Pulse wave tissue Doppler imaging
was taken at the septal side of mitral annulus. Early diastolic mitral
annular velocity (E’) and atrial mitral annular velocity (A’) were
measured. The ratio of E to A (E/A) and the ratio of E to E’ (E/E’)
were calculated [5,10,11]. All measurements were obtained from
3 cardiac cycles and the data were averaged.
2.6. Histopathological analysis
After continuous infusion of angiotensin II or saline for 14 days,
mice were sacriﬁced by cervical dislocation and hearts were rap-
idly excised. Whole heart weight (HW) and left ventricular weight
(LVW) were measured and normalized by body weight (BW) and
tibial length (TL). The parafﬁn-embedded heart sections were
stained with hematoxylin-eosin or Elastica-Masson. The photomi-
crographs of the sections stained with hematoxylin-eosin were
digitally taken, and cross-sectional area of cardiomyocytes was
measured using NIH ImageJ software (National Institutes of Health,
Bethesda, Maryland) [5,6]. Myocardial interstitial ﬁbrosis was as-
sessed by Elastica-Masson staining. The area of ﬁbrosis, which
was stained with blue collagen, was determined using Adobe
Photoshop CS2 (Adobe, San Jose, CA), and ﬁbrosis fraction was cal-
culated as the ratio of the blue color area to total cardiac area [5–
7].
2.7. Assessment of superoxide generation
The excised heart tissue was immediately frozen in liquid nitro-
gen with optimal cutting temperature compound and sectioned at
10-lm thickness [5]. The section was incubated with 10 lmol/l
dihydroethidium (DHE, Sigma–Aldrich Co., St. Louis, MO) at 37 C
for 30 min. The ﬂuorescent images were acquired using ﬂuores-
cence microscope (Olympus IX71, OLYMPUS Optical Co., Tokyo, Ja-
pan) and the mean DHE ﬂuorescence intensity of cardiomyocytes,
which were in 20 randomly selected ﬁelds in each section, was
quantitated with NIH imageJ software [5,12].
2.8. Senescence-associated b-galactosidase activity
Senescence-associated b-galactosidase (SA-b-gal) staining was
performed using fresh frozen sections (4-lm thickness) of the left
ventricular tissues according to the manufacturer’s protocol (Bio-
Vision Inc., Mountain View, CA) [5,13]. SA-b-gal positive cells were
visualized as blue color under light microscopy, and positive cells
for SA-b-gal activity were counted in 10 sections of each sample.
2.9. Reverse transcription polymerase chain reaction
Total RNA was extracted from the snap-frozen left ventricle
using TRIzol reagent (Invitrogen, Carlsbad, CA). The RNAs were re-
verse-transcribed (RT) into ﬁrst strand cDNAs, and the cDNAs were
subjected to PCR with PrimeScript RT-PCR Kit (Takara Bio Inc.,
Otsu, Japan) according to the manufacturer’s instructions [5–7].
Primers were designed on the basis of GenBank sequences (p21,
NM_001111099 and b-actin, NM_007393). Ampliﬁed PCR products
were resolved on 1% agarose gels and visualized by ethidium bro-
mide staining under ultraviolet illumination and photographed.
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software. Gene expression was normalized by b-actin as the inter-
nal standard and the results were expressed as a fold increase over
WT control [5–7].
2.10. Statistical analysis
All data were expressed as mean ± standard deviation (SD).
Comparisons of vitamin C levels at basal conditions between WT
mice and SMP30-TG mice were performed by an unpaired t-test.
All other parameters were evaluated by two-way analysis of vari-
ance (ANOVA) followed by multiple comparisons with Bonferroni
test using SPSS Statistics 17.0 (SPSS Japan Inc., Tokyo, Japan). A
probability value <0.05 was considered statistically signiﬁcant.Fig. 1. Cardiac hypertrophy in WT mice and SMP30-TG mice after angiotensin II
infusion. (A) Top, Representative images of light micrographs of hearts fromWT and
SMP30-TG mice with and without angiotensin II infusion. Bottom, hematoxylin and
eosin staining of myocardial cross sections. (B) Quantitative analysis of cross-
sectional area of cardiomyocytes from the left ventricle. Data are presented as
mean ± SD from 6 to 8 mice in each group. ⁄P < 0.01 vs. control in the same strain
mice; P < 0.01 vs. angiotensin II- infused WT mice.3. Results
3.1. Generation of SMP30-TG mice
Gene and protein expression levels of SMP30 were augmented
about ten-fold and ﬁve-fold in SMP30-TG mouse hearts compared
with WT mice, respectively. No neonatal and adult deaths were
seen in SMP30-TG mice. There was no abnormal ﬁnding on echo-
cardiography and microscopic examinations of multiple histologi-
cal sections of the heart (data not shown) in SMP30-TG mice.
Cardiac tissue concentration of vitamin C levels was not different
between SMP30-TG mice and WT mice (46.5 ± 6.6 vs.
45.7 ± 7.0 lg/g tissue).
3.2. Overexpression of SMP30 blocked angiotensin II-induced cardiac
hypertrophy and ﬁbrosis
BW, HW and LVW were similar between control WT mice and
SMP30-TG mice (Table 1). After angiotensin II infusion for 14 days,
both systolic and diastolic blood pressures were similarly elevated
in WT mice and SMP30-TG mice (Table 1). However, HW, LVW,
HW/BW, LVW/BW, HW/TL, and LVW/TL were signiﬁcantly lower
in SMP30-TG mice than in WT mice after angiotensin II infusion.
The cardiomyocyte cross sectional area was not different between
control WT and SMP30 TG mice (Fig. 1). Although angiotensin II
infusion increased cardiomyocyte cross sectional area, the increase
was less in SMP30-TG mice than in WT mice as shown in Fig. 1.Table 1
Gravimetric and hemodynamic data of WT and SMP30-TG mice.
Control Angiotensin II
WT SMP30-TG WT SMP30-TG
Gravimetric data
BW, g 26.8 ± 1.8 27.5 ± 1.8 25.8 ± 1.4 26.3 ± 1.8
HW, mg 129 ± 13 134 ± 8 163 ± 8⁄⁄ 145 ± 11⁄⁄
LVW, mg 90 ± 11 93 ± 9 123 ± 8⁄⁄ 110 ± 10⁄⁄
HW/BW, mg/g 4.8 ± 0.4 4.9 ± 0.3 6.3 ± 0.5⁄⁄ 5.6 ± 0.7⁄⁄
LVW/BW, mg/g 3.3 ± 0.3 3.4 ± 0.2 4.8 ± 0.4⁄⁄ 4.2 ± 0.6⁄⁄
HW/TL, mg/mm 6.1 ± 0.6 6.3 ± 0.3 7.7 ± 0.4⁄⁄ 6.8 ± 0.5⁄⁄
LVW/TL, mg/mm 4.2 ± 0.5 4.4 ± 0.4 5.8 ± 0.4⁄⁄ 5.2 ± 0.4⁄⁄
Hemodynamic data
HR, bpm 595 ± 84 576 ± 63 513 ± 80 524 ± 59
SBP, mmHg 104 ± 5 105 ± 8 146 ± 8⁄⁄ 146 ± 6⁄⁄
DBP, mmHg 68 ± 9 64 ± 6 93 ± 13⁄⁄ 96 ± 11⁄⁄
MAP, mmHg 80 ± 8 78 ± 6 111 ± 11⁄⁄ 113 ± 9⁄⁄
BW, indicates body weight; HW, heart weight; LVW, left ventricular weight; TL,
tibial length; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood
pressure; and MAP, mean arterial pressure. Data are presented as mean ± SD from
10 to 15 mice in each group.
⁄⁄P < 0.01 vs. control in the same strain mice.
P < 0.05.
P < 0.01 vs. angiotensin II-infused WT mice.There were no signiﬁcant differences in ﬁbrosis fraction at basal
condition between WT and SMP30-TG mice (Fig. 2). Although
angiotensin II induced interstitial ﬁbrosis in both WT and SMP30
TG mice, the extent of myocardial ﬁbrosis was signiﬁcantly lower
in SMP30-TG mice than in WTmice after angiotensin II stimulation
as shown in Fig. 2. These data revealed that the cardiac-speciﬁcFig. 2. Myocardial ﬁbrosis in WT mice and SMP30-TG mice after angiotensin II
infusion. (A) Representative images of Elastica-Masson staining of myocardial
sections. (B) The percent area of myocardial interstitial ﬁbrosis in the left ventricle.
Data are presented as mean ± SD from 6 to 8 mice in each group. ⁄P < 0.01 vs.
control in the same strain mice; P < 0.01 vs. angiotensin II-infused WT mice.
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hypertrophy and ﬁbrosis, independently of elevated blood
pressure.Fig. 3. Myocardial oxidative stress in WT mice and SMP30-TG mice after angio-
tensin II infusion. (A) Representative images of dihydroethidium (DHE) staining of
frozen left ventricular tissues. (B) Bar graphs show quantiﬁcation of superoxide
generation. Results are mean ± SD from 5 to 6 mice in each group. ⁄P < 0.01 vs.
control in the same strain mice; P < 0.01 vs. angiotensin II-infused WT mice.3.3. SMP30 preserved angiotensin II-induced cardiac diastolic function
Echocardiography showed that each parameter was not differ-
ent between control WT mice and SMP30-TG mice (Table 2). After
angiotensin II infusion, thickness of intraventricular septum and
posterior wall, and calculated LV mass in SMP30-TG mice were sig-
niﬁcantly lower than those in WT mice. Left ventricular ejection
fraction did not change in either WT mice or SMP30-TG mice fol-
lowing angiotensin II infusion. To evaluate left ventricular diastolic
function, pulse Doppler imaging of left ventricular inﬂow and pulse
wave tissue Doppler imaging at the mitral annulus were per-
formed. In SMP30-TG mice, 40% of mice (4/10) showed a relaxation
abnormality pattern (E/A < 1), whereas all of WT mice (10/10)
showed a pseudo-normalization pattern (E/A > 1) after angiotensin
II infusion. In addition, E/E’ in SMP30-TG mice was lower than that
in WT mice after angiotensin II stimulation as shown in Table 2.
These data indicated that not only cardiac hypertrophy but also
diastolic function was preserved in SMP30-TG mice after angioten-
sin II stimulation.3.4. SMP30 blocked angiotensin II-induced myocardial oxidative stress
To assess the effect of SMP30 expression on myocardial oxida-
tive stress, we performed DHE staining, which indicates the super-
oxide levels. Left ventricular sections with the ﬂuorescence probe
DHE demonstrated that superoxide generation was not different
between WT mice and SMP30-TG mice at basal condition (Fig. 3).
However, after angiotensin II stimulation, the increase of superox-
ide generation in SMP30-TG mice was signiﬁcantly lower than that
in WT mice as shown in Fig. 3. This ﬁnding demonstrated that car-
diac-speciﬁc overexpression of SMP30 attenuated angiotensin II-
induced superoxide generation.Table 2
Echocardiography of WT and SMP30-TG mice.
Control Angiotensin II
WT SMP30-TG WT SMP30-TG
IVS, mm 0.71 ± 0.05 0.73 ± 0.06 0.91 ± 0.07** 0.84 ± 0.11**,
PW, mm 0.78 ± 0.07 0.75 ± 0.04 0.95 ± 0.10** 0.88 ± 0.07**,
LVEDD, mm 3.77 ± 0.37 3.70 ± 0.26 3.68 ± 0.31 3.53 ± 0.26
LVESD, mm 2.52 ± 0.32 2.54 ± 0.36 2.52 ± 0.35 2.44 ± 0.32
FS, % 33.2 ± 4.4 32.3 ± 6.1 31.8 ± 4.7 32.0 ± 5.3
EF, % 62.4 ± 6.7 60.9 ± 8.1 60.4 ± 7.1 60.7 ± 7.6
LV mass, mg 96.1 ± 18.2 90.7 ± 13.4 126.0 ± 16.5** 106.5 ± 9.4**,
E velocity,
mm/s
503 ± 63 513 ± 85 499 ± 95 442 ± 150
A velocity,
mm/s
302 ± 93 312 ± 51 307 ± 110 292 ± 124
E/A 1.82 ± 0.70 1.67 ± 0.26 1.49 ± 0.23 1.09 ± 0.47
E’ velocity,
mm/s
18.7 ± 5. 5 18.3 ± 2.8 12.7 ± 3.7* 13.7 ± 3.3*
E/E’ 29.0 ± 6.8 28.2 ± 3.6 42.2 ± 8.3** 32.6 ± 10.0**,
IVS, indicates intraventricular septum; PW, posterior wall thickness; LVEDD, left
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimen-
sion; FS, fractional shortening; EF, ejection fraction; E, peak early diastolic left
ventricular ﬁlling velocity; A, peak atrial ﬁlling velocity; and E’, early diastolic
mitral annular velocity.
Results are mean ± SD from 8 to 12 mice in each group.
* P < 0.05.
** P < 0.01 vs. control in same strain mice.
 P < 0.05.
 P < 0.01 vs. angiotensin II-infused WT mice.3.5. SMP30 attenuated cellular senescence after angiotensin II infusion
Senescent cells can be identiﬁed by the expression of enzymatic
SA-b-gal activity in left ventricular tissues. There were no SA b-gal
positive cells in control WT mice and SMP30-TG mice (Fig. 4A).
Angiotensin II induced SA-b-gal positive cells in left ventricular
myocardium, and the numbers of SA-b-gal positive cells were sig-
niﬁcantly lower in SMP30-TG mice than in WT mice (Fig. 4A). To
evaluate the gene expression of cell cycle inhibitor to conﬁrm car-
diac cellular senescence, we performed RT-PCR analysis. The re-
sults of RT-PCR demonstrated that p21 gene expression was
signiﬁcantly suppressed in SMP30-TG mice compared with WT
mice after angiotensin II infusion (Fig. 4B). Neither p16 nor p53
gene expression was different between 2 groups (data not shown).
These results indicated that overexpression of SMP30 effectively
attenuated cardiac cellular senescence after angiotensin II infusion
by p21-dependent pathway.
4. Discussion
In this study, we demonstrated that cardiac-speciﬁc overex-
pression of SMP30 inhibited angiotensin II-induced cardiac hyper-
trophy, ﬁbrosis and diastolic dysfunction. SMP30 also suppressed
superoxide generation and senescence markers including p21 gene
expression after angiotensin II infusion. Recently, we have shown
that deﬁciency of SMP30 exacerbates angiotensin II-induced car-
diac hypertrophy, left ventricular dysfunction and adverse remod-
eling. Interestingly, the present data of SMP30-TG mice reversed
those phenotypes observed in SMP30-KO mice. These data suggest
that SMP30 could be a novel therapeutic target to prevent cardiac
remodeling and diastolic dysfunction, especially due to
hypertension.
SMP30 gene is highly conserved among vertebrates, indicating a
crucial physiological function of SMP30 in all mammals [2]. More-
over, SMP30 is widely distributed in almost all organs including
heart. Calorie restriction, which is thought to be anti-aging and
anti-oxidative actions, effectively suppressed age-related down-
regulation of SMP30 expression [14]. These ﬁndings suggested that
SMP30 expression is inﬂuenced by oxidative stress, and SMP30 is
assumed to behave as an anti-aging factor. While the physiological
function of SMP30 remains entirely unclear, previous studies have
Fig. 4. Senescence markers in the hearts of WTmice and SMP30-TG mice after angiotensin II infusion. (A) Senescent cells were detected by SA b-gal staining of left ventricular
tissue sections (upper panels), and the numbers of SA b-gal-positive cells were counted (lower bar graph). (B) The mRNA expression levels of p21 gene were analyzed by RT-
PCR. Expression levels of p21 gene were normalized by b-actin. Results are mean ± SD from 6 to 8 mice in each group. ⁄P < 0.01 vs. control in the same strain mice; P < 0.01 vs.
angiotensin II-infused WT mice.
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causes various dysfunctions of organs during aging process [3,4]. In
addition, it has been reported that SMP30 has multiple functions
such as Ca2+ regulator (named as regucalcin) [15], anti-oxidant
[16], and enzymatic ability to hydrolyze diisopropyl phosphoroﬂu-
oridate [17]. Recently, SMP30 has been identiﬁed as glucolacton-
ase, which is a key enzyme for L-ascorbic acid (vitamin C)
biosynthesis in mammals, although human beings are unable to
synthesize vitamin C because of mutations in L-gulonolactone oxi-
dase [18]. In the present study, tissue concentrations of vitamin C
level were not different between WT mice and SMP30-TG mice.
Aging is an important risk factor of cardiovascular diseases such
as hypertension, left ventricular hypertrophy and heart failure
[19]. With aging, the heart shows age-related changes in cardiac
structure and function [20]. An increase in oxidant stress with
aging is implicated in age-related cardiac remodeling [21]. On
the other hand, it is appreciated that renin-angiotensin system
(RAS) plays a key role in the development of cardiac remodeling
and heart failure. Many experimental studies have showed that
RAS activation mediates oxidative stress in the heart, and there-
fore, inhibition of RAS may reverse age-related cardiac remodeling
by suppressive effects of cardiac oxidative stress [22]. Thus, it is
considered that control of oxidative stress may have inﬂuence on
cardiac remodeling and that suppression of oxidative stress can
protect the heart against aging. In the present study, angiotensin
II-induced superoxide generation was inhibited in the heart of
SMP30-TG mice. In addition, cardiac cellular senescence due to
angiotensin II was blocked in SMP30-TG mice.
In summary, cardiac-speciﬁc overexpression of SMP30 inhibited
angiotensin II-induced cardiac hypertrophy, ﬁbrosis and impaired
diastolic function, suggesting that SMP30 has a cardio-protective
role with anti-oxidative and anti-aging effects. Up-regulation of
SMP30 could attenuate the development of heart failure and be a
novel strategy to approach senescent cardiac diseases.
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